A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING)
一项随机、双臂（1:1 比例）、双盲、安慰剂对照的 III 期试验，旨在评估利妥昔单抗治疗 MCD/FSGS 患者新发或复发性 NS 的疗效、安全性、成本和成本效益 (TURING)
期刊:BMC Nephrology
影响因子:2.4
doi:10.1186/s12882-024-03576-0
C Willcocks, Lisa; Qian, Wendi; Cader, Ruzaika; Gatley, Katrina; Siddiqui, Hira; Tabebisong, Endurance; Champion, Karlena; Kronbichler, Andreas; Lightstone, Liz; Jayne, David; Wilson, Edward; Griffith, Megan
